Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
Chevalier B, Dimario C, Neumann FJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Coe J, Schwartz LB; ZOMAXX I Investigators. Chevalier B, et al. Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1039-47. doi: 10.1002/ccd.24958. Epub 2013 Jul 25. Catheter Cardiovasc Interv. 2013. PMID: 23592567 Clinical Trial.
A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y, Sauguet A, Desgranges P, Feugier P, Rosset E, Ducasse E, Kaladji A, Salomon du Mont L, Pernès JM, Commeau P, Lermusiaux P, Leclere B, Guyomarc'h B, Hoffmann CT, Maurel B. Gouëffic Y, et al. Among authors: commeau p. JACC Cardiovasc Interv. 2020 Feb 24;13(4):447-457. doi: 10.1016/j.jcin.2019.12.028. JACC Cardiovasc Interv. 2020. PMID: 32081238 Free article. Clinical Trial.
Two-year outcomes after percutaneous coronary intervention with drug-eluting stents or bare-metal stents in elderly patients with coronary artery disease.
Lafont A, Sinnaeve PR, Cuisset T, Cook S, Sideris G, Kedev S, Carrie D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-Bermudez E, Ferre JM, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice MC, Varenne O; SENIOR investigators. Lafont A, et al. Among authors: commeau p. Catheter Cardiovasc Interv. 2021 Apr 1;97(5):E607-E613. doi: 10.1002/ccd.29159. Epub 2020 Aug 6. Catheter Cardiovasc Interv. 2021. PMID: 32761890 Free article. Clinical Trial.
Use and outcomes of the PK Papyrus covered stent in France: SOS PK Papyrus Registry.
Hernández-Enríquez M, Belle L, Madiot H, Pansieri M, Souteyrand G, de Poli F, Piot C, Boueri Z, Gerbaud E, Boiffard E, Benamer H, Lattuca B, Commeau P, Gervasoni R, Rangé G, Lhoest N, Marliere S, Abdellaoui M, Delarche N, Zemour G, Armengaud J, Carre M, Levesque S, Boudou N. Hernández-Enríquez M, et al. Among authors: commeau p. Catheter Cardiovasc Interv. 2021 Nov 1;98(5):874-881. doi: 10.1002/ccd.29328. Epub 2020 Oct 21. Catheter Cardiovasc Interv. 2021. PMID: 33085150
2-Year Results With a Sirolimus-Eluting Self-Expanding Stent for Femoropopliteal Lesions: The First-in-Human ILLUMINA Study.
Steiner S, Honton B, Langhoff R, Chiesa R, Kahlberg A, Thieme M, Zeller T, Garot P, Commeau P, Cremonesi A, Marone EM, Sauguet A, Scheinert D. Steiner S, et al. Among authors: commeau p. JACC Cardiovasc Interv. 2022 Mar 28;15(6):618-626. doi: 10.1016/j.jcin.2021.12.034. Epub 2022 Feb 23. JACC Cardiovasc Interv. 2022. PMID: 35219622 Free article.
141 results